13 Nov 2025

Goodwin advises Vidi Capital on acquisition of Centre d'Imagerie du Languedoc (CIL11)

"Goodwin advised Vidi Capital on its acquisition of the Centre d'Imagerie du Languedoc (CIL11). The deal strengthens Vidi Capital's position in diagnostic and therapeutic medical imaging in France as it pursues consolidation of independent imaging businesses."

Goodwin advised Vidi Capital in connection with its acquisition of the Centre d'Imagerie du Languedoc (CIL11). The transaction consists of Vidi Capital’s acquisition of the Centre d'Imagerie du Languedoc, a recognised provider of advanced diagnostic imaging services in the Aude department. With this acquisition, Vidi Capital consolidates its presence in diagnostic and therapeutic medical imaging and further positions itself as a major national player. Founded in 2022 by the radiologists of the Vidi network — the largest independent radiology network in France with nearly 1,250 members — Vidi Capital proposes an innovative consolidation model for independent medical imaging. The firm’s stated objectives are to guarantee excellence of care and to address the sector’s principal challenges amid a period of significant recomposition. Goodwin represented client(s) Vidi Capital with a team composed by: William Robert, partner (corporate); William Ducrocq Ferre, associate (corporate); Charles-Henri de Gouvion Saint-Cyr, partner (tax); Paul Fournière, associate (tax); Adrien Paturaud, partner (finance); Alexander Hahn, associate (finance); Elisa Revel, associate (finance); Jad Bezzari, associate (finance).
Read the full story

Register for free to access daily news.

Register Free
We use cookies to improve your experience, analyze traffic, and serve targeted ads. Read our Cookie Policy.

Cookie Preferences

Customize your cookie settings. Necessary cookies are always enabled.

Strictly Necessary

Required for the website to function (e.g. login, security).

Analytics & Statistics

Help us understand how visitors interact with the website.

Marketing & Ads

Used to deliver relevant ads and track effectiveness.